Ann: AstraZeneca selected Adherium Smartinhaler for its study, page-14

We seem to be following similar names !. All of which look to me to be potential turnaround cases.

With ADR, having Astra sign a contract is great, but IMO, this Board has been led down the garden path by a broker identifying a Company in desperate need of funds and wanting a sweet payday for themselves and their clients.

ADR need to start generating some revenues and get cashflow neutral at least so the brokers can't bamboozle them with fairy dust. First step in that direction is sorting out staff costs which are far too high. Entire 9 month cash deficit is caused by staff and admin costs - not R&D, not manufacturing,

I like the product and the sector and I will give the new CEO 6 more months to kick some goals.